Some patients with CD30+ ALCL treated with Brentuximab vedotin (BV), an anti CD30 chimeric antibody, have subsequently relapsed with CD30‐disease, suggesting a potential mechanism of failure.16, 17. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.